BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 2731312)

  • 1. Effective reinduction therapy for childhood acute nonlymphoid leukemia using simultaneous continuous infusions of teniposide and amsacrine.
    Mirro J; Kalwinsky DK; Grier HE; Santana VM; Mason C; Murphy SB; Dahl GV
    Cancer Chemother Pharmacol; 1989; 24(2):123-7. PubMed ID: 2731312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teniposide (VM-26) and continuous infusion cytosine arabinoside for initial induction failure in childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
    Ochs J; Rivera GK; Pollock BH; Buchanan G; Crist W; Freeman AI
    Cancer; 1990 Oct; 66(8):1671-7. PubMed ID: 2208021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
    Feldman EJ; Alberts DS; Arlin Z; Ahmed T; Mittelman A; Baskind P; Peng YM; Baier M; Plezia P
    J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of combined methotrexate and teniposide infusions prior to reinduction therapy in relapsed childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study.
    Ochs J; Rodman J; Abromowitch M; Kavanagh R; Harris M; Yalowich J; Rivera GK
    J Clin Oncol; 1991 Jan; 9(1):139-44. PubMed ID: 1985163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I trial of carboplatin and etoposide given as continuous infusions to adults with leukemia.
    Lee EJ; Reck K; Carter C; Hodges S; Schiffer CA
    Leukemia; 1993 Oct; 7(10):1500-3. PubMed ID: 8412310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [4'-(9-acridinylamino)-methanesulfon-m-aniside (AMSA) combination salvage therapy in refractory acute non-lymphocytic leukemia in adults].
    Mukaiyama T; Ogawa M; Horikoshi N; Inoue K; Fukutani H; Tabata M; Hirano A; Mizunuma N; Itami S
    Gan To Kagaku Ryoho; 1989 May; 16(5):2019-23. PubMed ID: 2730091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of continuous-infusion amsacrine and teniposide for the treatment of relapsed childhood acute nonlymphocytic leukemia.
    Petros WP; Rodman JH; Mirro J; Evans WE
    Cancer Chemother Pharmacol; 1991; 27(5):397-400. PubMed ID: 1999001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous infusion etoposide/carboplatin for treatment of refractory acute leukemia.
    Letendre L; Noel P; Tefferi A; Solberg LA; Gastineau DA; Hoagland HC
    Am J Clin Oncol; 1995 Oct; 18(5):382-4. PubMed ID: 7572751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of chronic myelogenous leukemia in blast crisis and in accelerated phase with high- or intermediate-dose cytosine arabinoside and amsacrine.
    Bauduer F; Delmer A; Blanc MC; Delmas-Marsalet B; Cadiou M; Rio B; Marie JP; Zittoun R
    Leuk Lymphoma; 1993 Jun; 10(3):195-200. PubMed ID: 8220118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
    Dinndorf PA; Avramis VI; Wiersma S; Krailo MD; Liu-Mares W; Seibel NL; Sato JK; Mosher RB; Kelleher JF; Reaman GH
    J Clin Oncol; 1997 Aug; 15(8):2780-5. PubMed ID: 9256119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of continuous infusion 6-thioguanine in patients with acute leukemia.
    Powell BL; Lyerly ES; Motsinger CP; Cruz JM; Chorley HM; Hurd DD; Cooper MR
    Leukemia; 1995 May; 9(5):770-3. PubMed ID: 7769838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful reinduction therapy with amsacrine and cyclocytidine in acute nonlymphoblastic leukemia in children. A report from the Childrens Cancer Study Group.
    Miller LP; Pyesmany AF; Wolff LJ; Rogers PC; Siegel SE; Wells RJ; Buckley JD; Hammond GD
    Cancer; 1991 May; 67(9):2235-40. PubMed ID: 1707336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies.
    Larson RA; Geller RB; Janisch L; Milton J; Grochow LB; Ratain MJ
    Cancer Chemother Pharmacol; 1995; 36(3):204-10. PubMed ID: 7781139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia.
    Kantarjian HM; Beran M; O'Brien S; Robertson L; Siddik Z; Yoshida M; Yang LY; Rios MB; Keating MJ; Meyer M
    Leukemia; 1996 Mar; 10(3):396-401. PubMed ID: 8642853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous infusion diaziquone and etoposide: a phase I study in adult patients with acute leukemia.
    Lee EJ; Reck K; Schiffer CA
    Leukemia; 1990 Mar; 4(3):189-92. PubMed ID: 2314118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous infusion of mitoxantrone combined with high-dose cytarabine in refractory/relapsed acute myeloblastic leukemia and blast crisis of chronic myelogenous leukemia.
    Linkesch W; Thaler J; Gattringer C; Konwalinka G
    Haematol Blood Transfus; 1990; 33():330-2. PubMed ID: 2323638
    [No Abstract]   [Full Text] [Related]  

  • 17. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).
    Jehn U; Heinemann V; Wilmanns W
    Anticancer Res; 1989; 9(1):119-24. PubMed ID: 2705739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity trials of amsacrine (AMSA) and etoposide +/- azacitidine (AZ) in childhood acute non-lymphocytic leukemia (ANLL): a pilot study.
    Steuber CP; Holbrook T; Camitta B; Land VJ; Sexauer C; Krischer J
    Invest New Drugs; 1991 May; 9(2):181-4. PubMed ID: 1714886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous infusion chemotherapy with epirubicin and vincristine in relapsed and refractory acute leukemia.
    Liso V; Specchia G; Pavone V; Capalbo S; Dione R
    Acta Haematol; 1990; 83(3):116-9. PubMed ID: 2109448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
    Sung WJ; Kim DH; Sohn SK; Kim JG; Baek JH; Jeon SB; Moon JH; Ahn BM; Lee KB
    Jpn J Clin Oncol; 2005 Oct; 35(10):612-6. PubMed ID: 16172175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.